Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • For Subscribers
    • For Advertisers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Tranilast Inhibits Cytokine-Induced Nuclear Factor κB Activation in Vascular Endothelial Cells

Martin Spiecker, Ioana Lorenz, Nikolaus Marx and Harald Darius
Molecular Pharmacology October 2002, 62 (4) 856-863; DOI: https://doi.org/10.1124/mol.62.4.856
Martin Spiecker
1Department of Medicine II, University of Bochum, Bochum, Germany (M.S.); 2Department of Medicine II, University of Mainz, Mainz, Germany (I.L., H.D.); 3Department of Medicine II, University of Ulm, Ulm, Germany (N.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ioana Lorenz
1Department of Medicine II, University of Bochum, Bochum, Germany (M.S.); 2Department of Medicine II, University of Mainz, Mainz, Germany (I.L., H.D.); 3Department of Medicine II, University of Ulm, Ulm, Germany (N.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikolaus Marx
1Department of Medicine II, University of Bochum, Bochum, Germany (M.S.); 2Department of Medicine II, University of Mainz, Mainz, Germany (I.L., H.D.); 3Department of Medicine II, University of Ulm, Ulm, Germany (N.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harald Darius
1Department of Medicine II, University of Bochum, Bochum, Germany (M.S.); 2Department of Medicine II, University of Mainz, Mainz, Germany (I.L., H.D.); 3Department of Medicine II, University of Ulm, Ulm, Germany (N.M.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Tranilast [N-(3,4-dimethoxycinnamoyl)anthranilic acid] inhibits vascular inflammation. However, the relevant anti-inflammatory mechanisms are not completely understood. We studied the effects of tranilast on nuclear factor-κB (NF-κB)-dependent endothelial cell adhesion molecule expression and transcriptional regulation. Cultured human umbilical vein endothelial cells were preincubated with 12.5 to 100 μg/ml tranilast. Tumor necrosis factor-α (TNF-α)-induced endothelial VCAM-1, ICAM-1, and E-selectin surface expression was inhibited dose dependently. Maximal inhibition achieved with 100 μg/ml tranilast was 38 ± 6.9, 31.8 ± 1.5, and 31.9 ± 1.9%, respectively (mean ± S.E.M.,p < 0.001, n = 5). Secretion of interleukin 6, which is also NF-κB–sensitive, was significantly inhibited by tranilast. Endothelial MHC-I expression, which is independent of NF-κB, was not inhibited. Although cytokine-induced degradation of NF-κB inhibitor proteins (IκB-α, -β, and -ε), nuclear translocation of NF-κB, and binding of NF-κB to κBcis-acting elements in the adhesion molecule promoters were not affected by tranilast, ICAM-1-κB and E-selectin-κB reporter gene activity was inhibited by 53% (n = 5, p < 0.01) and 51% (n = 5,p < 0.001), respectively. In contrast, using SP-1 and C/EBP constructs, reporter gene activity was not altered. Expression of the transcriptional coactivator cAMP response element binding protein binding protein (CBP) was inhibited by tranilast, resulting in a loss of interaction between NF-κB and CBP. Therefore, in therapeutically relevant concentrations (50 μg/ml), tranilast inhibits NF-κB-dependent transcriptional activation by interfering with the NF-κB/CBP association. We propose that inhibition of NF-κB dependent gene transcription contributes to the anti-inflammatory effects of tranilast.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

Log in using your username and password

Forgot your user name or password?

Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 62 (4)
Molecular Pharmacology
Vol. 62, Issue 4
1 Oct 2002
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Tranilast Inhibits Cytokine-Induced Nuclear Factor κB Activation in Vascular Endothelial Cells
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
Citation Tools
Research ArticleArticle

Tranilast Inhibits Cytokine-Induced Nuclear Factor κB Activation in Vascular Endothelial Cells

Martin Spiecker, Ioana Lorenz, Nikolaus Marx and Harald Darius
Molecular Pharmacology October 1, 2002, 62 (4) 856-863; DOI: https://doi.org/10.1124/mol.62.4.856

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Tranilast Inhibits Cytokine-Induced Nuclear Factor κB Activation in Vascular Endothelial Cells

Martin Spiecker, Ioana Lorenz, Nikolaus Marx and Harald Darius
Molecular Pharmacology October 1, 2002, 62 (4) 856-863; DOI: https://doi.org/10.1124/mol.62.4.856
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Coordinated Transcriptional Regulation of Cytochrome P450 3As by Nuclear Transcription Factor Y (NF-Y) and Specificity Protein 1 (Sp1)
  • Protocol-dependent differences in IC50 values measured in hERG assays occur in a predictable way and can be used to quantify state preference of drug binding.
  • Statins perturb Gβγ signaling and cell behaviors in a Gγ subtype dependent manner
Show more Article

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2019 by the American Society for Pharmacology and Experimental Therapeutics